PRKAA2 and metabolic dysfunction-associated steatotic liver disease: The activation of AMPK and its subsequent downstream signaling pathway of lipid metabolism reduces the accumulation of triglycerides, fatty acids and cholesterol in the liver and attenuates the development of NAFLD [13].